SPRO - Spero Therapeutics, Inc.
| Previous Close | 11.85 |
| Open | 11.84 |
| Bid | 10.25 x 900 |
| Ask | 0.00 x 1400 |
| Day's Range | 11.79 - 12.46 |
| 52 Week Range | 5.52 - 18.23 |
| Volume | 38,660 |
| Avg. Volume | 80,301 |
| Market Cap | 215.718M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.16 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.00 |
CNBC Videos•3 months agoThe travel industry is extremely resilient, says Expedia CEO
Expedia President and CEO Mark Okerstrom joins "Squawk on the Street" to discuss the company's strong earnings and what the state of travel is for the United States and around the world.
- Zacks•14 days ago
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 62.34% and 517.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire•14 days ago
Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review
CAMBRIDGE, Mass., May 09, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.
- Bloomberg•21 days ago
Expedia Shares Fall as Home-Rental Business Vrbo Goes Slow
Wall Street was looking for $2.69 billion, according to data compiled by Bloomberg. Revenue growth from Vrbo slowed to 14 percent. Bellevue, Washington-based Expedia has been struggling to chase rivals Airbnb Inc. and Booking Holdings Inc. in the fast-growing and lucrative market for short-term rentals with its HomeAway and Vrbo services.
- Zacks•21 days ago
Analysts Estimate Spero Therapeutics, Inc. (SPRO) to Report a Decline in Earnings: What to Look Out for
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•22 days ago
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Spero (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The options have an exercise price of $11.18 per share, which is equal to the closing price of Spero’s common stock on April 30, 2019. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36-months, subject to each employee’s continued employment with Spero on such vesting dates. The options are subject to the terms and conditions of Spero’s 2019 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.
- Skift•24 days ago
Marriott Is Officially Getting Into the Homesharing Business
Marriott, the world’s largest hotel company with more than 7,000 hotels around the world, is officially getting into the homesharing business with the launch of Homes & Villas by Marriott International in 100 destinations. A year after it began conducting a homesharing pilot, the 91-year-old hotel group appears convinced it can compete with travel disruptors […] The post Marriott Is Officially Getting Into the Homesharing Business appeared first on Skift.
- GlobeNewswire•last month
Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
CAMBRIDGE, Mass., April 08, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.
- Zacks•2 months ago
Spero Gets Fast Track Designation for SPR994, Shares Improve
Spero???s (SPRO) SPR994 receives Fast Track designation by the FDA for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis.
- GlobeNewswire•2 months ago
Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis
CAMBRIDGE, Mass., March 29, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.
- GlobeNewswire•2 months ago
Spero Announces Appointment of Cynthia Smith to its Board of Directors
Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced the appointment of Cynthia Smith to its Board of Directors, effective as of today. “We are pleased to welcome Cynthia to our Board of Directors,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.
- Zacks•2 months ago
Will Spero Therapeutics Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Spero Therapeutics.
- Business Wire•2 months ago
Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review
Anticipated 2019 Events include Enrollment in the Planned SPR994 Pivotal Phase 3 Clinical Trial and Top-Line Data from SPR720 and SPR206 Phase 1 Clinical Trials in 2H19
- Associated Press•2 months ago
Airbnb, HomeAway lose legal challenge to Santa Monica rules
Short-term rental sites Airbnb and HomeAway lost a legal challenge Wednesday against an ordinance enacted by a popular California tourist city. The ordinance imposed several obligations involving rental sites in seaside Santa Monica, including refraining from booking properties that are not licensed and listed on a city registry. A 9th U.S. Circuit Court of Appeals panel ruled that a lower court properly dismissed the legal challenge over its failure to state a claim against the city.
- Bloomberg•2 months ago
Airbnb Loses Major Fight Over California City's Rental Law
The ruling Wednesday by a three-judge panel of the Ninth Circuit is a setback for the home-sharing platforms in their effort to avoid regulation by cities that blame the rapid proliferation of short-term rentals for a shortage of affordable housing and a disintegration of residential communities. The Santa Monica ordinance holds the companies responsible for booking rentals of residences that aren’t licensed by the city. San Francisco-based Airbnb is the largest home-rental platform with more than 6 million listings around the world.
- GlobeNewswire•3 months ago
Spero Therapeutics to Present at March Investor Conferences
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections. Spero’s lead product candidate, SPR994, is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Spero has begun start-up activities for the ADAPT-PO Phase 3 clinical trial of SPR994 for the treatment of complicated urinary tract infections and anticipates opening trial sites to support study enrollment in the first quarter of 2019. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of non-tuberculous mycobacterial (NTM) infections. In January 2019, Spero initiated a Phase 1 clinical trial of SPR720 in healthy subjects and expects top-line data from this trial in the second half of 2019.
- GlobeNewswire•3 months ago
Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720
CAMBRIDGE, Mass., Feb. 26, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.
- Simply Wall St.•3 months ago
Are Spero Therapeutics, Inc.’s (NASDAQ:SPRO) Interest Costs Too High?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Spero Therapeutics, Inc. (NASDAQ:SPRO), which has zero-debt on its balanceRead More...
- Bloomberg•3 months ago
Expedia Analysts Grow More Bullish After Strong Earnings
While growth in Expedia’s home rental service disappointed, the company made up for it with strength in its core platform. Cowen also sees positive read-through to peers Booking Holdings Inc. and TripAdvisor Inc., which report later this month. “HomeAway was the major disappointment” in the fourth quarter and the lack of prior warning from management suggested it must have started to deteriorate at the end of the year, after third-quarter results.
Motley Fool•3 months agoExpedia Group Inc. (EXPE) Q4 2018 Earnings Conference Call Transcript
EXPE earnings call for the period ending December 31, 2018.
- Bloomberg•3 months ago
Expedia Shares Jump After 2019 Earnings Forecast Beats Estimates
Adjusted earnings before interest, tax, depreciation and amortization, will grow 10 percent to 15 percent in 2019, Chief Financial Officer Alan Pickerill said on a conference call Thursday. Analysts were projecting an increase of 9 percent, according to data compiled by Bloomberg. Analysts were looking for signs that Expedia’s performance would justify a runaway share price so far this year.
- GlobeNewswire•4 months ago
Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994
“With the FDA’s acceptance of our IND application for SPR994, we are excited to continue our Phase 3 initiation efforts, including opening clinical trial sites for enrollment in the U.S.," said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.
- GlobeNewswire•4 months ago
Spero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial
“SPR720 is a promising drug candidate that has the potential to become the first approved oral treatment for NTM infections. NTM infections cause chronic, debilitating disease and represent an area of high unmet need as there are no specifically approved orally administered treatment options,” said Ankit Mahadevia, M.D., CEO of Spero Therapeutics. The Phase 1 clinical trial evaluating SPR720 is a double-blind, placebo-controlled, ascending dose, multi-cohort study in healthy subjects consisting of single ascending dose and multiple ascending dose cohorts.
- Benzinga•4 months ago
The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) ( reported positive ...
